Recursion Pharmaceuticals Inc Cl A (RXRX)

$4.40 +0.04 (0.92%)
Market Cap 2.27B
Revenue (ttm) 58.84M
Net Income (ttm) -463.66M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -788.00%
Debt to Equity Ratio 0.01
Volume 9,422,100
Avg Vol 39,745,469
Day's Range N/A - N/A
Shares Out 519.84M
Stochastic %K 30%
Beta 0.94
Analysts Sell
Price Target $7.00

Company Profile

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4...

Industry: Biotechnology
Sector: Healthcare
Phone: 385 269 0203
Fax: 801 821 2872
Address:
41 South Rio Grande Street, Salt Lake City, United States
nokej13957
nokej13957 Dec. 25 at 9:25 AM
$RXRX
0 · Reply
dbz_HKD_og
dbz_HKD_og Dec. 25 at 6:04 AM
$RXRX
0 · Reply
Shaffin786
Shaffin786 Dec. 25 at 5:36 AM
$RXRX • RXRX is no longer a “concept stock.” • It’s becoming a platform + pipeline biotech with: • a near-term late-stage rare disease shot • multiple oncology readouts queued • improved capital stewardship I’d frame it as: 2025 = setup year 2026 = validation year If FAP advances cleanly, RXRX stops being valued as “AI biotech optionality” and starts being valued as a multi-asset developer — that’s when upside can compound meaningfully.
0 · Reply
Jbear236
Jbear236 Dec. 25 at 4:13 AM
$RXRX if I’m reading it right the have $650 million in cash
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 25 at 1:57 AM
$RXRX Current Stock Price: $4.41 Contracts to trade: $5 RXRX Dec 26 2025 Call Entry: $0.03 Exit: $0.04 ROI: 37% Hold ~23 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
MakingMoney20
MakingMoney20 Dec. 25 at 1:45 AM
$RXRX Cathie Wood Is Doubling Down on Recursion Pharmaceuticals Stock. RXRX $$
0 · Reply
MakingMoney20
MakingMoney20 Dec. 25 at 1:44 AM
$RXRX Enjoy the Fishes! Happy Holidays Ya'll
0 · Reply
MakingMoney20
MakingMoney20 Dec. 25 at 1:43 AM
$RXRX Cathie Wood’s trades often read like a quiet manifesto – what she buys signals confidence, what she trims hints at fading faith. In the week ended Dec. 19, that message was clear. ARK Investment Management leaned harder into AI-led biotechnology and crypto, while paring back exposure to consumer tech and electric-vehicle heavyweights. At the center of that shift sat Recursion Pharmaceuticals (RXRX). ARK snapped up more than 2.8 million RXRX shares, worth about $13.4 million, spread across ARK Genomic Revolution ETF (ARKG) and flagship ARK Innovation ETF (ARKK). The additions lifted Recursion to the No. 27 holding in ARKK RXRX $$
0 · Reply
ryancartwright
ryancartwright Dec. 24 at 9:03 PM
$RXRX Accumulating at this level starting today!!! c💪🏻💪🏻💪🏻💪🏻💪🏻company has solid cash reserves and is using AI for the business model going forward💪🏻
0 · Reply
shooshmonk
shooshmonk Dec. 24 at 8:30 PM
$RXRX just started looking more into Recursion and to a much less serious extent, $DNA, i was more optimistic about Recursion until I started doing a few Google searches.
0 · Reply
Latest News on RXRX
Recursion Pharmaceuticals: Upgrading To Buy - My Most Surprising Call Of 2025

Dec 18, 2025, 11:38 AM EST - 6 days ago

Recursion Pharmaceuticals: Upgrading To Buy - My Most Surprising Call Of 2025

What's Happening With RXRX Stock?

Dec 18, 2025, 11:05 AM EST - 6 days ago

What's Happening With RXRX Stock?

Recursion Pharmaceuticals, Inc. (RXRX) Discusses Updated Safety and Efficacy Data from TUPELO Phase I/II Study of REC-4881 in FAP Transcript

Dec 8, 2025, 4:37 PM EST - 16 days ago

Recursion Pharmaceuticals, Inc. (RXRX) Discusses Updated Safety and Efficacy Data from TUPELO Phase I/II Study of REC-4881 in FAP Transcript

Recursion Pharma's AI-powered therapy reduces colon growth in a rare disease trial

Dec 8, 2025, 7:32 AM EST - 16 days ago

Recursion Pharma's AI-powered therapy reduces colon growth in a rare disease trial

Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks

Dec 8, 2025, 7:30 AM EST - 16 days ago

Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks

Jim Cramer: This Health Care Stock Has Been 'Horrendous'

Dec 5, 2025, 8:19 AM EST - 19 days ago

Jim Cramer: This Health Care Stock Has Been 'Horrendous'

Recursion Announces Webinar For Upcoming Clinical Data Readout on the TUPELO Phase 1b/2 Trial of REC-4881 in Familial Adenomatous Polyposis on December 8, 2025

Dec 1, 2025, 8:30 AM EST - 23 days ago

Recursion Announces Webinar For Upcoming Clinical Data Readout on the TUPELO Phase 1b/2 Trial of REC-4881 in Familial Adenomatous Polyposis on December 8, 2025

Recursion Pharmaceuticals, Inc. (RXRX) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 21, 2025, 7:43 PM EST - 4 weeks ago

Recursion Pharmaceuticals, Inc. (RXRX) Presents at Jefferies London Healthcare Conference 2025 Transcript

Recursion Pharmaceuticals: What To Make Of This AI-Based Drug Discovery Leader?

Nov 18, 2025, 10:14 AM EST - 5 weeks ago

Recursion Pharmaceuticals: What To Make Of This AI-Based Drug Discovery Leader?

Recursion Pharmaceuticals, Inc. (RXRX) Q3 2025 Earnings Call Transcript

Nov 5, 2025, 8:11 PM EST - 7 weeks ago

Recursion Pharmaceuticals, Inc. (RXRX) Q3 2025 Earnings Call Transcript

Recursion Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 5, 2025, 6:30 AM EST - 7 weeks ago

Recursion Reports Third Quarter 2025 Financial Results and Provides Business Update

Recursion Announces CEO Transition Plan to Drive Next Phase of Growth

Nov 5, 2025, 6:28 AM EST - 7 weeks ago

Recursion Announces CEO Transition Plan to Drive Next Phase of Growth

Recursion to Participate in Upcoming Investor Conferences

Nov 4, 2025, 8:00 AM EST - 7 weeks ago

Recursion to Participate in Upcoming Investor Conferences

Recursion to Report Third Quarter 2025 Business Updates and Financial Results on November 5th

Oct 28, 2025, 8:00 AM EDT - 2 months ago

Recursion to Report Third Quarter 2025 Business Updates and Financial Results on November 5th

Looking For The Next Beyond Meat? Here Are The Top 10 Most Shorted Stocks

Oct 22, 2025, 1:42 PM EDT - 2 months ago

Looking For The Next Beyond Meat? Here Are The Top 10 Most Shorted Stocks

AI APLD ENVX HIMS IBRX PLUG RKT

What's Going On With Recursion Pharmaceuticals Stock On Wednesday?

Oct 8, 2025, 2:51 PM EDT - 2 months ago

What's Going On With Recursion Pharmaceuticals Stock On Wednesday?

Recursion Pharmaceuticals, Inc. (RXRX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Sep 8, 2025, 8:03 PM EDT - 3 months ago

Recursion Pharmaceuticals, Inc. (RXRX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Recursion Pharmaceuticals, Inc. (RXRX) Presents At Citi's Biopharma Back To School Conference Transcript

Sep 3, 2025, 6:51 PM EDT - 4 months ago

Recursion Pharmaceuticals, Inc. (RXRX) Presents At Citi's Biopharma Back To School Conference Transcript

Recursion Pharmaceuticals, Inc. (RXRX) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 2:44 PM EDT - 5 months ago

Recursion Pharmaceuticals, Inc. (RXRX) Q2 2025 Earnings Call Transcript

Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 5, 2025, 6:30 AM EDT - 5 months ago

Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update

Recursion to Report Second Quarter 2025 Business Updates and Financial Results on August 5th

Jul 29, 2025, 8:00 AM EDT - 5 months ago

Recursion to Report Second Quarter 2025 Business Updates and Financial Results on August 5th

How Palantir, Tempus, Nvidia-Backed Recursion Are Disrupting Big Pharma

Jul 25, 2025, 1:53 PM EDT - 5 months ago

How Palantir, Tempus, Nvidia-Backed Recursion Are Disrupting Big Pharma

NVDA PLTR

Top 2 Health Care Stocks You May Want To Dump This Quarter

Jul 22, 2025, 7:02 AM EDT - 5 months ago

Top 2 Health Care Stocks You May Want To Dump This Quarter

MEDP

Recursion to lay off 20% of workforce, narrows focus amid biotech downturn

Jun 10, 2025, 6:14 AM EDT - 7 months ago

Recursion to lay off 20% of workforce, narrows focus amid biotech downturn

MIT and Recursion Release Boltz-2: Next Generation AI Model to Predict Binding Affinity at Unprecedented Speed, Scale, and Accuracy

Jun 6, 2025, 10:00 AM EDT - 7 months ago

MIT and Recursion Release Boltz-2: Next Generation AI Model to Predict Binding Affinity at Unprecedented Speed, Scale, and Accuracy

Recursion Pharmaceuticals, Inc. (RXRX) Q1 2025 Earnings Call Transcript

May 5, 2025, 1:37 PM EDT - 8 months ago

Recursion Pharmaceuticals, Inc. (RXRX) Q1 2025 Earnings Call Transcript

Recursion Reports First Quarter 2025 Financial Results and Provides Business Update

May 5, 2025, 6:00 AM EDT - 8 months ago

Recursion Reports First Quarter 2025 Financial Results and Provides Business Update

Recursion Pharmaceuticals: Looking For Entry Around Q1 Earnings

May 5, 2025, 4:02 AM EDT - 8 months ago

Recursion Pharmaceuticals: Looking For Entry Around Q1 Earnings

Preliminary Phase 1b/2 Data for REC-4881 in Familial Adenomatous Polyposis (FAP) Demonstrates Reduced Polyp Burden

May 4, 2025, 12:45 PM EDT - 8 months ago

Preliminary Phase 1b/2 Data for REC-4881 in Familial Adenomatous Polyposis (FAP) Demonstrates Reduced Polyp Burden

Recursion to Report First Quarter 2025 Business Updates and Financial Results on May 5th

Apr 28, 2025, 8:27 AM EDT - 8 months ago

Recursion to Report First Quarter 2025 Business Updates and Financial Results on May 5th

Recursion to Present Preliminary Clinical Data from the Ongoing Phase 1b/2 trial of REC-4881 in FAP at Digestive Disease Week 2025

Apr 22, 2025, 8:34 PM EDT - 8 months ago

Recursion to Present Preliminary Clinical Data from the Ongoing Phase 1b/2 trial of REC-4881 in FAP at Digestive Disease Week 2025

HealthVerity Partners with Recursion to Enhance Clinical Trial Analytics with Real-World Data

Apr 16, 2025, 8:30 AM EDT - 9 months ago

HealthVerity Partners with Recursion to Enhance Clinical Trial Analytics with Real-World Data

Recursion and Enamine Release New AI-Enabled Targeted Compound Libraries

Apr 9, 2025, 8:00 AM EDT - 9 months ago

Recursion and Enamine Release New AI-Enabled Targeted Compound Libraries

Recursion to Participate in Upcoming Investor Conference

Apr 1, 2025, 8:00 AM EDT - 9 months ago

Recursion to Participate in Upcoming Investor Conference

Recursion Pharmaceuticals' Update Could Shed Light On Pipeline, Cost-Saving Plans, Analyst Says

Mar 3, 2025, 11:19 AM EST - 10 months ago

Recursion Pharmaceuticals' Update Could Shed Light On Pipeline, Cost-Saving Plans, Analyst Says

Recursion Pharmaceuticals, Inc. (RXRX) Q4 2024 Earnings Call Transcript

Feb 28, 2025, 1:16 PM EST - 10 months ago

Recursion Pharmaceuticals, Inc. (RXRX) Q4 2024 Earnings Call Transcript

Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results

Feb 28, 2025, 6:30 AM EST - 10 months ago

Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results

Recursion to Report Fourth Quarter and Fiscal Year 2024 Business Updates and Financial Results on February 28th

Feb 24, 2025, 8:00 AM EST - 10 months ago

Recursion to Report Fourth Quarter and Fiscal Year 2024 Business Updates and Financial Results on February 28th

Altitude Lab Startups Raise $154M in Capital

Feb 18, 2025, 11:00 AM EST - 11 months ago

Altitude Lab Startups Raise $154M in Capital

Recursion: CDK7 Inhibitor Differentiation Is Initially Paying Off

Feb 13, 2025, 6:05 PM EST - 11 months ago

Recursion: CDK7 Inhibitor Differentiation Is Initially Paying Off

Recursion Presents Phase 2 Data for REC-994 in CCM in Late-Breaking Oral Presentation at the International Stroke Conference

Feb 5, 2025, 5:24 PM EST - 11 months ago

Recursion Presents Phase 2 Data for REC-994 in CCM in Late-Breaking Oral Presentation at the International Stroke Conference

Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More

Jan 7, 2025, 9:15 AM EST - 1 year ago

Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More

Recursion to Present at 43rd Annual JP Morgan Healthcare Conference

Jan 6, 2025, 8:30 AM EST - 1 year ago

Recursion to Present at 43rd Annual JP Morgan Healthcare Conference

Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules

Dec 20, 2024, 4:05 PM EST - 1 year ago

Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules

Recursion: Transforming Drug Discovery With Its AI-Powered Drug Development Platform

Dec 12, 2024, 6:07 AM EST - 1 year ago

Recursion: Transforming Drug Discovery With Its AI-Powered Drug Development Platform

Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability

Dec 9, 2024, 6:00 PM EST - 1 year ago

Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability

Recursion: Undruggable CDK12 Protein Target Might Be Possible With REC-1245

Dec 9, 2024, 3:14 PM EST - 1 year ago

Recursion: Undruggable CDK12 Protein Target Might Be Possible With REC-1245

Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery

Nov 20, 2024, 7:00 AM EST - 1 year ago

Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery

Recursion and Exscientia Shareholders Approve the Proposed Combination

Nov 13, 2024, 9:08 AM EST - 1 year ago

Recursion and Exscientia Shareholders Approve the Proposed Combination

Recursion Announces the Release of OpenPhenom-S/16 in Google Cloud's Model Garden

Nov 12, 2024, 4:54 PM EST - 1 year ago

Recursion Announces the Release of OpenPhenom-S/16 in Google Cloud's Model Garden

nokej13957
nokej13957 Dec. 25 at 9:25 AM
$RXRX
0 · Reply
dbz_HKD_og
dbz_HKD_og Dec. 25 at 6:04 AM
$RXRX
0 · Reply
Shaffin786
Shaffin786 Dec. 25 at 5:36 AM
$RXRX • RXRX is no longer a “concept stock.” • It’s becoming a platform + pipeline biotech with: • a near-term late-stage rare disease shot • multiple oncology readouts queued • improved capital stewardship I’d frame it as: 2025 = setup year 2026 = validation year If FAP advances cleanly, RXRX stops being valued as “AI biotech optionality” and starts being valued as a multi-asset developer — that’s when upside can compound meaningfully.
0 · Reply
Jbear236
Jbear236 Dec. 25 at 4:13 AM
$RXRX if I’m reading it right the have $650 million in cash
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 25 at 1:57 AM
$RXRX Current Stock Price: $4.41 Contracts to trade: $5 RXRX Dec 26 2025 Call Entry: $0.03 Exit: $0.04 ROI: 37% Hold ~23 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
MakingMoney20
MakingMoney20 Dec. 25 at 1:45 AM
$RXRX Cathie Wood Is Doubling Down on Recursion Pharmaceuticals Stock. RXRX $$
0 · Reply
MakingMoney20
MakingMoney20 Dec. 25 at 1:44 AM
$RXRX Enjoy the Fishes! Happy Holidays Ya'll
0 · Reply
MakingMoney20
MakingMoney20 Dec. 25 at 1:43 AM
$RXRX Cathie Wood’s trades often read like a quiet manifesto – what she buys signals confidence, what she trims hints at fading faith. In the week ended Dec. 19, that message was clear. ARK Investment Management leaned harder into AI-led biotechnology and crypto, while paring back exposure to consumer tech and electric-vehicle heavyweights. At the center of that shift sat Recursion Pharmaceuticals (RXRX). ARK snapped up more than 2.8 million RXRX shares, worth about $13.4 million, spread across ARK Genomic Revolution ETF (ARKG) and flagship ARK Innovation ETF (ARKK). The additions lifted Recursion to the No. 27 holding in ARKK RXRX $$
0 · Reply
ryancartwright
ryancartwright Dec. 24 at 9:03 PM
$RXRX Accumulating at this level starting today!!! c💪🏻💪🏻💪🏻💪🏻💪🏻company has solid cash reserves and is using AI for the business model going forward💪🏻
0 · Reply
shooshmonk
shooshmonk Dec. 24 at 8:30 PM
$RXRX just started looking more into Recursion and to a much less serious extent, $DNA, i was more optimistic about Recursion until I started doing a few Google searches.
0 · Reply
estatebuyersmia
estatebuyersmia Dec. 24 at 6:58 PM
$RXRX 2026 WILL BE THE YEAR OF BIOTECH BUYOUTS...
0 · Reply
estatebuyersmia
estatebuyersmia Dec. 24 at 6:26 PM
$RXRX MERRY CHRISTMAS TO ALL THE BULLS AND SCREW THE BEARS
1 · Reply
hihir81198
hihir81198 Dec. 24 at 5:47 PM
$RXRX
0 · Reply
mankind1
mankind1 Dec. 24 at 5:26 PM
$RXRX I still have high hopes
0 · Reply
GrosseEier
GrosseEier Dec. 24 at 5:25 PM
$RXRX pipeline is good! Sanofi just bought Dynavax. We are next!!!!
0 · Reply
DeepValueStocks
DeepValueStocks Dec. 24 at 4:42 PM
$RXRX Goldman Sachs loves RXRX for 2026 ! " RXRX's incoming CEO Najat Khan and CFO Ben Taylor discussed their key priorities: (1) translating insights from the AI-levered Recursion OS platform to differentiated clinical data - most recently, with the positive Ph1/2 REC-4881 data in familial adenomatous polyposis (FAP), where aligning with the FDA on pivotal design/endpoints is the key next step; (2) focused platform investments in high-value areas; and (3) financial discipline, including a high bar for advancement. Management also touched on the oncology programs, noting: REC-617 (CDK7) combination data in ovarian cancer in 1H27; first Ph1 data for REC-1245 (RBM39) in biomarker-enriched solid tumors/lymphoma in 1H26 and REC-3565 (MALT1) in B-cell malignancies in 1H27; and preclinical PI3Kα H1047R inhibitor REC-7735. Overall, we see the narrative changing for RXRX as it enters into late-stage development in FAP, and remain focused on execution on the prioritized programs."
0 · Reply
Katili
Katili Dec. 24 at 4:22 PM
$RXRX 5500 shares not sale for 2 years minimum
1 · Reply
Etrading
Etrading Dec. 24 at 4:21 PM
$OMER about to buy $8S area yesterday but was loading $RXRX ; well knew pump was coming ! $ASTS so many dumb here did not understand my $92 alert take profit and buy cheaper. Anyway your loss if you don’t listen my alerts! $AVGO still holding some since $327 alert $SPY
0 · Reply
GrosseEier
GrosseEier Dec. 24 at 3:45 PM
$RXRX Sandi is on the buying streak! Are we next, currently we are on strategic partnership with Sanofi!!!
2 · Reply
huntingforBear
huntingforBear Dec. 24 at 3:40 PM
$RXRX What a garbage! What a greedy and incompetent management!
1 · Reply
RobDuran
RobDuran Dec. 24 at 3:09 PM
$RXRX I had Dynavax 2 years ago, great gains...let's hope for RxRx
0 · Reply
DeepValueStocks
DeepValueStocks Dec. 24 at 3:08 PM
$RXRX Got in today *TA is favorable *Recent JPM target raise to $11 *Backed by NVDA and many savvy institutions *Growing pipeline & revs *Cash runway till late (27) *High institutional ownership (73.57%/Fintel) *AI-powered therapy(REC-4881) reduces polyp growth in a rare disease trial
4 · Reply